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Abstract
Background: Expression of correct neurotransmitters is crucial for normal nervous system function.
How neurotransmitter expression is regulated is not well-understood; however, previous studies provide
evidence that both environmental signals and intrinsic differentiation programs are involved. One
environmental signal known to regulate neurotransmitter expression in vertebrate motoneurons is
Hepatocyte growth factor, which acts through the Met receptor tyrosine kinase and also affects other
aspects of motoneuron differentiation, including axonal extension. Here we test the role of Met in
development of motoneurons in embryonic zebrafish.
Results:  We found that met  is expressed in all early developing, individually identified primary
motoneurons and in at least some later developing secondary motoneurons. We used morpholino
antisense oligonucleotides to knock down Met function and found that Met has distinct roles in primary
and secondary motoneurons. Most secondary motoneurons were absent from met morpholino-injected
embryos, suggesting that Met is required for their formation. We used chemical inhibitors to test several
downstream pathways activated by Met and found that secondary motoneuron development may depend
on the p38 and/or Akt pathways. In contrast, primary motoneurons were present in met morpholino-
injected embryos. However, a significant fraction of them had truncated axons. Surprisingly, some CaPs in
met morpholino antisense oligonucleotide (MO)-injected embryos developed a hybrid morphology in
which they had both a peripheral axon innervating muscle and an interneuron-like axon within the spinal
cord. In addition, in met MO-injected embryos primary motoneurons co-expressed mRNA encoding
Choline acetyltransferase, the synthetic enzyme for their normal neurotransmitter, acetylcholine, and
mRNA encoding Glutamate decarboxylase 1, the synthetic enzyme for GABA, a neurotransmitter never
normally found in these motoneurons, but found in several types of interneurons. Our inhibitor studies
suggest that Met function in primary motoneurons may be mediated through the MEK1/2 pathway.
Conclusion: We provide evidence that Met is necessary for normal development of zebrafish primary
and secondary motoneurons. Despite their many similarities, our results show that these two
motoneuron subtypes have different requirements for Met function during development, and raise the
possibility that Met may act through different intracellular signaling cascades in primary and secondary
motoneurons. Surprisingly, although met is not expressed in primary motoneurons until many hours after
they have extended axons to and innervated their muscle targets, Met knockdown causes some of these
cells to develop a hybrid phenotype in which they co-expressed motoneuron and interneuron
neurotransmitters and have both peripheral and central axons.
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Background
Although different subtypes of motoneurons of inverte-
brate species use different neurotransmitters to activate
muscle [1,2], all vertebrate motoneurons activate muscle
via release of acetylcholine (ACh) [3]. Historically verte-
brate motoneurons have been considered exclusively
cholinergic. However, several recent studies provide evi-
dence that mammalian spinal motoneurons release both
ACh and glutamate from collaterals within the spinal cord
that synapse with inhibitory interneurons known as Ren-
shaw cells, although ACh is still thought to be the only
neurotransmitter that mediates motoneuron activation of
skeletal muscle [4-6]. It is unknown how two distinct neu-
rotransmitters are differentially regulated within these
motoneurons. But the importance of appropriate regula-
tion is underscored by a recent study showing that forced
expression of neurotransmitters other than ACh in frog
motoneurons causes inappropriate expression of non-
cholinergic receptors at the neuromuscular junction [7].
Expression of the correct neurotransmitter is crucial for
normal nervous system function, although the mecha-
nisms that establish appropriate neurotransmitter expres-
sion are not well understood. Interneurons in the chick
spinal cord can be induced to express ACh inappropriately
by forced expression of MNR2, Lhx3, or Islet1 transcrip-
tion factors [8,9]. However, forced expression of these
transcription factors causes the interneurons to initiate a
program of motoneuron differentiation [8,9] for which
ACh is the appropriate neurotransmitter, suggesting that
neurotransmitter expression is established by programs
that specify cell fate. On the other hand, it is well-known
that at least some neural crest-derived neurons of the
peripheral nervous system normally change their neuro-
transmitter phenotypes during development, and that this
is regulated by environmental signals [10,11]. These stud-
ies show that under some conditions, neurotransmitter
expression is altered in response to the environment after
cell fate is specified. Consistent with this idea, changing
calcium-mediated neural activity can regulate neurotrans-
mitter expression in neurons in culture [12] and in vivo
[7] without affecting expression of markers of cell fate
specification [7]. Together these studies suggest that regu-
lation of neurotransmitter phenotype is complex and
involves both intrinsic factors that regulate differentiation
programs as well as responses to environmental signals.
One environmental signal known to affect neurotransmit-
ter phenotype in motoneurons is Hepatocyte growth fac-
tor (HGF; also known as Scatter factor). Axotomy of adult
hypoglossal motoneurons leads to a dramatic loss of
mRNA and protein of the ACh synthetic enzyme, choline
acetyltransferase (ChAT); this loss can be prevented by
administration of HGF [13]. HGF has also been shown to
stimulate choline acetyltransferase activity in motoneu-
rons in vitro [14]. HGF acts through the Met receptor tyro-
sine kinase [15], which is expressed in motoneurons and
has been shown to be important for their development.
For example, HGF acts through Met as an axonal attract-
ant and survival factor for some populations of mamma-
lian and avian motoneurons [14,16-22] and has also been
shown to be required to recruit a subpopulation of
motoneurons to a specific motor pool [23].
Experiments carried out using a variety of cell types have
shown that activation of Met can initiate intracellular sig-
naling through several different downstream cascades,
including mitogen activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K) and p38 and Akt
pathways [24,25]. These cascades can act independently
or can be stimulated simultaneously, and there can be
crosstalk among them [26-28]. In addition to activation
via Met, these intracellular signaling pathways can also be
activated by other receptors [29-33]. To elucidate the roles
of these pathways in cellular events, a number of specific
pathway inhibitory reagents have been developed, includ-
ing LY294002, which inhibits the PI3K pathway [34],
U0126, which inhibits the MAPK pathway by inhibiting
MEK1/2 [35], and SB203580, which inhibits Akt [36] and
p38 MAP kinase [37] (Figure 1). It is currently unknown
which of these signaling cascades is activated by HGF-
Blocking Met function Figure 1
Blocking Met function. (a) RT-PCR showing that the E6I6 
MO blocks met mRNA splicing. (b) Activation of Met can ini-
tiate intracellular signaling through several different down-
stream cascades, including MEK1/2 and PI3K [24,25]. This 
diagram shows the cascade and where specific inhibitors act. 
See text for details.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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mediated Met signaling in motoneurons, and whether dif-
ferent cascades affect different aspects of HGF-mediated
Met function in these cells.
In the present study, we have taken advantage of the
experimental tractability of embryonic zebrafish to inves-
tigate the role of Met in motoneuron differentiation.
Development of zebrafish spinal motoneurons has been
well-characterized [38]. Zebrafish have two waves of
motoneuron differentiation: primary and secondary
motoneurons. Primary motoneurons (PMNs) constitute a
small set of segmentally reiterated cells generated during
gastrulation [38,39]. Each PMN is individually identified
based on its morphology and gene expression pattern.
Within each spinal hemisegment, CaP has the most cau-
dally located cell body, RoP has the most rostrally located
cell body, and MiP has a cell body located between CaP
and RoP. Some spinal hemisegments have an additional
PMN, called VaP, which is essentially a duplicated CaP
that typically dies [40]. PMN axons pioneer nerve path-
ways followed later by axons of secondary motoneurons
(SMNs) [41,42]. SMNs are born later than PMNs and are
more numerous [38]. SMNs are born [43] and extend
axons [42] over a protracted period of development; sev-
eral studies suggest that there are distinct subsets of SMNs
[44-47], although this has not yet been studied in detail.
In addition to extensive characterization of their develop-
ment, many recent studies have characterized the physio-
logical properties of zebrafish motoneurons and how
motoneurons are driven by interneurons to activate vari-
ous types of behavior (see [38]). The neurotransmitters of
zebrafish spinal interneurons have been extensively char-
acterized. Specific subsets of interneurons have been
shown to be glycinergic or glutamatergic [48,49]. In addi-
tion, several types of interneurons have been shown to
express the neurotransmitter gamma-amino butyric acid
(GABA) [48-50].
A previous study showed that zebrafish met is a specific
marker of CaP and VaP [51]. We report here that a few
hours later, met is also expressed in MiP and RoP, and that
even later in development met  is expressed in at least
some, perhaps all, SMNs. We used morpholino antisense
oligonucleotides (MOs) to knock down Met function and
found that this had distinct effects on SMNs and PMNs.
Many SMNs required Met for their differentiation and the
SMN population was significantly reduced in met MO-
injected embryos. In contrast, PMN differentiation
appeared normal in met MO-injected embryos. However,
some PMNs had truncated peripheral axons or developed
interneuron-like processes within the spinal cord. In addi-
tion, in the absence of Met many PMNs inappropriately
expressed GABA. Whether vertebrate motoneurons ever
normally express GABA is controversial, and we return to
this point in the discussion. To learn whether distinct Met-
activated signaling cascades are responsible for the differ-
ent phenotypes we observed following Met knock down,
we used inhibitors that affect different pathways down-
stream of Met activation. Our results suggest that the p38
and/or Akt cascade may be required for SMN differentia-
tion, whereas the MEK1/2 cascade may be required for
appropriate neurotransmitter expression and to prevent
formation of interneuron-like axons in PMNs. Together
our results suggest that Met acts through different path-
ways to affect different aspects of motoneuron develop-
ment.
Materials and Methods
Animal husbandry and lines
Zebrafish embryos were obtained from natural spawning
of AB or AB/TU wild-type or mn2Et (also referred to as
pargmn2Et) [52], Tg(gata2:GFP)  [53] and Tg(pax2a:GFP)
[54] transgenic lines. Fish were staged by hours post-ferti-
lization at 28.5°C (hpf) [55].
Cloning of zebrafish chat and met
We amplified two fragments, 1,400 bp and 900 bp from
cDNA from a mixture of 24 hpf and 48 hpf embryos; the
1,400 bp fragment was amplified using primers CAT3 and
CAT6 and the 900 bp fragment was amplified using prim-
ers CAT5 and CAT6. The fragments were cloned into
TOPO-TA vector, sequenced and tested for specific expres-
sion patterns. Primer sequences were:
CAT3, 5'-ACAGGTTAGCACTACCTGTC-3';
CAT5, 5'-CTGAATGACAGCAACAGACG-3';
CAT6: 5'-TGGTCCGTCTGAGGATTGTAG-3'.
We cloned a 1.1 kb fragment of zebrafish met from cDNA
from a mixture of 24 hpf and 48 hpf embryos using prim-
ers zfmetE1-1 and zfmetE1-2. The fragment was cloned
into PCRII-TOPO and verified by sequence and expres-
sion pattern. Primer sequences were:
zfmetE1-1, 5'-ATGTGAGGAACCAATAGAAAGC-3';
zfmetE1-2, 5'-CAGATCCTGGAAAGTGACGG-3'.
Downregulation of Met
To knock down Met activity, we used three MOs (Gene-
Tools; Philomath, OR, USA): CM1a and CM2 were
designed to block met  (ENSDART00000104456; NCBI
Entrez GeneID 492292) translation; these are the same
MOs used by Haines and colleagues [56], thus, we
repeated their experiments, showing the absence or reduc-
tion of myoD RNA expression in fin myoblasts in MO-
injected embryos at 48 hpf, to verify that these MOs
worked. CM1a was designed to anneal to ATG-containingNeural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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sequences and CM2 was targeted against the 5' untrans-
lated region of met. We also used an additional MO, E6I6,
which was designed to block met mRNA splicing, leading
to a deletion of exon 6 and a truncation of the Met pro-
tein. We determined that the E6I6 MO blocked met mRNA
splicing by RT-PCR (Figure 1a). As a control, we used an
MO similar to CM1a, but containing a 5 bp mismatch
(CM1a-5 mm). About 2–4 nl of MO, diluted in water,
were injected into the cytoplasm of one-cell-stage
embryos. For most experiments, CM1a and CM2 were
injected together, at concentrations at which each MO
alone had no effect (CM1a, 0.6 mM; CM2, 0.8 mM);
throughout this paper, embryos injected with a combina-
tion of CM1a and CM2 are referred to as met MO-injected
embryos. Injection of E6I6 resulted in essentially the same
phenotypes as injection of CM1a, CM2 or a mixture of the
two translation blockers. MO sequences and concentra-
tions were:
CM1a, 5'-ATAGTGAATTGTCATCTTTGTTCCT-3', 0.7–1.0
mM;
CM2, 5'-CTGTAAAATAAAGACACCTGTCGGA-3', 0.9–1.2
mM;
E6I6, 5'-GATTTGTGATGACTCTTACCACAAA-3', 0.7–1.0
mM;
CM1a-5 mm, 5'-ATACTCAATTCTCATGTTTCTTCCT-3',
1.0 mM;
underlines represent mismatches.
In some experiments we co-injected mouse Met mRNA
(mMet in pSP64; generous gift of G. Vande Woude, Van
Andel Research Institute, Grand Rapids, MI, USA) [15]
together with the MOs. As a further control to test whether
RNA diluted the MO to a non-effective concentration, we
performed a set of control experiments in which we
injected a similar amount of lacZ  mRNA,  mMet  RNA,
together with the MOs. Injection of lacZ mRNA alone did
not affect neuronal development. In contrast, injection of
lacZ mRNA plus MOs resulted in a phenotype similar to
injection of MOs alone, showing that any effects of mMet
RNA plus MO injections were specific to the mMet mRNA.
Blocking Met downstream effectors with pharmacological 
inhibitors
Met activates a number of different signaling pathways
[15,57,58] and inhibitors that block these pathways have
been previously used to test Met function (see Figure 1b)
[24]. We used the following inhibitors to test Met func-
tion in zebrafish: U0126 (InvivoGen; San Diego, CA,
USA), which blocks MEK1 and MEK2 [35], LY294002
(InvivoGen), which blocks PI3K [34], and SB203580
Zebrafish met is expressed in developing spinal motoneurons Figure 2
Zebrafish met is expressed in developing spinal 
motoneurons. All photographs are dorsal to the top and 
anterior to the left; this is also the case for subsequent fig-
ures except where noted. (a) A 22 hpf embryo showing met 
RNA expression in one cell of a spinal hemisegment (aster-
isk). (b) A 22 hpf embryo showing co-expression of met 
(green) and islet2 (red) in CaP and VaP. (c) A 26 hpf embryo 
showing met expression in all four PMNs in this spinal 
hemisegment. (d) A 48 hpf embryo showing met expression 
in eight cells (asterisks) in this hemisegment. (e) A 48 hpf 
gata2:GFP transgenic embryo showing GFP expression in ven-
trally projecting SMNs (green) and met expression (red) in a 
subset of these cells. The axon of the SMN labeled with an 
asterisk is shown as it projects out of the spinal cord toward 
its ventral muscle target. The inset to the left shows the 
same SMN, also marked with an asterisk, in only the red 
channel, clearly revealing that the SMN expresses met RNA. 
(f) A 48 hpf mn2Et transgenic embryo showing GFP expres-
sion (green) in PMNs and SMNs; met (red) is expressed in a 
subset of these cells. (g-j) mn2Et transgenic embryos at 24 
hpf showing GFP expression in motoneurons: posterior seg-
ment showing GFP expression in CaP (g); posterior segment 
showing GFP expression in CaP and VaP (h); a more anterior 
segment showing GFP expression in CaP and MiP (i); an even 
more anterior segment showing GFP expression in CaP, VaP, 
MiP, RoP and several SMNs (j). Note that even as late as 5 
days post-fertilization, in mn2Et embryos GFP-positive cells 
in the spinal cord all appear to have peripheral axons and no 
interneuron-like cells express GFP, suggesting that in the 
mn2Et line GFP is expressed exclusively in motoneurons. 
Scale bars, 10 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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(InvivoGen) which blocks p38 and Akt [36,37]. Because
LY294002 had severe effects on overall development, we
did not pursue its effects on motoneuron differentiation.
For the inhibitor studies, embryos were dechorionated
and incubated in embryo medium. Cell permeable inhib-
itor was added at 16 hpf; embryos remained in the inhib-
itor solution until further processed at either 26 hpf or 48
hpf. We performed dose-response experiments to deter-
mine the optimal inhibitor concentrations to use for
experiments. We tested concentrations between 10 and
120  μM. In both cases we found that concentrations
below 50 μM had no effect and concentrations above 80
μM were deleterious to embryonic development. There-
fore, we used both U0126 and SB203580 at 60 μM.
RNA in situ hybridization and immunohistochemistry
RNA  in situ hybridization and immunohistochemistry
were carried out according to standard protocols [59].
RNA in situ hybridization
The following antisense RNA probes were used: islet2
(isl2) [60], glutamate decarboxylase 1 (gad1, also known as
gad67 [48]), met (1.1 kb fragment spanning 1–1,165 bp of
NCBI sequence AY687384; Entrez GeneID: 492292) and
chat (900 bp fragment spanning 1,099–1,967 of NCBI
sequence XM682602; Entrez GeneID: 559274).
Immunohistochemistry
The following primary antibodies were used: JL-8 mouse
anti-GFP (Chemicon; Temecula, CA, USA) was used at
1:200; zn1 (University of Oregon) was used at 1:150;
znp1 (University of Oregon) was used at 1:750; rabbit
anti-GABA (Sigma; St. Louis, MO, USA) was used at
1:1,000; anti-Alcam (Alcam was previously known as DM-
GRASP, Neurolin, zn5 antigen, and zn8 antigen; Univer-
sity of Oregon) was used at 1:4,000; F59 [61] was used at
1:10; 4D9 [62] was used at 1:50. Primary antibodies were
revealed using secondary antibodies coupled to Alexa
Fluor568 (goat anti-rabbit 1:1,000; Invitrogen-Molecular
Probes; Eugene, OR, USA); Alexa Fluor488 (goat anti-
mouse 1:1,000; Invitrogen-Molecular Probes); Alexa
Fluor546 (goat anti-mouse IgG1, 1:1,000; Invitrogen-
Molecular Probes); Alexa Fluor488 (goat anti-mouse
IgG2a, 1:1,000; Invitrogen-Molecular Probes); Alexa
Fluor546 (goat anti-mouse IgG2b, 1:1,000; Invitrogen-
Molecular Probes).
To reveal ACh receptor (AChR) clusters, embryos were
fixed at 4°C for 4 h, rinsed in phosphate-buffered saline,
incubated in 5 μg/ml α-bungarotoxin (αBTX-546; Invitro-
gen-Molecular Probes) in incubation buffer [phosphate
buffered saline plus 0.1% Tween/20 (PBT) + 1% dimethyl
sulfoxide (DMSO) + 5% normal goat serum (NGS)] for 30
minutes at room temperature, rinsed in PBT, and then fol-
lowed by a regular immunohistochemistry protocol
(adapted from [63] with minor modification).
Embryos were scored and photographed with a Zeiss Axi-
oplan microscope and photographed using a Nikon
Coolpix 995 digital camera or imaged using a Zeiss LSM5
confocal microscope.
Normal touch-evoked movements require Met function Figure 3
Normal touch-evoked movements require Met func-
tion. Embryos are oriented anterior to the top and viewed 
from dorsal. (a) Control embryo (top panel), head embed-
ded in agarose, responded to touch by bending away from 
the probe (asterisk); times indicated are milliseconds. A met 
MO-injected embryo (bottom panel) responded to touch sig-
nificantly more slowly than the control. Data from the con-
trol and met MO-injected embryo are shown on the same 
time scale. (b) The same embryos as in (a), but for each 
embryo the entire time-course of the movement is shown. 
The entire touch response took about 50 ms in the control 
embryo, but took about 190 ms in the MO-injected embryo, 
which remained in the coiled position for about 60 ms. Red 
box indicates maximal bending. (c) Black arrows display the 
time span of one touch response, as shown in (b), for control 
and met MO-injected embryos; the red section indicates the 
time the embryo stayed in a coiled position. (d) Time frame 
in which control and injected embryos stayed in the coiled 
position [red in (b,c)]. The differences between control and 
control MO-injected embryos were not significantly differ-
ent, but they were both significantly different from met MO-
injected embryos (p < 2.6 × 10-13, n = 46 touch-evoked 
responses of 8 control embryos and 32 touch-evoked 
responses of 8 met MO-injected embryos; p < 1.07 × 10-7, n 
= 22 touch-evoked responses of 4 control MO-injected 
embryos and 32 touch-evoked responses of 8 met MO-
injected embryos.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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Acridine orange staining
For characterization of cell death, embryos were stained
according to Williams and Holder [64], with minor mod-
ifications. Briefly, embryos were incubated for 20 minutes
in 5 mg/ml Acridine Orange (Sigma) in embryo medium,
washed three times for 5 minutes in embryo medium and
observed under fluorescence microscopy with an fluoro-
iso-thio-cyanate (FITC) filter.
Behavioral assay
We used high-speed imaging to monitor trunk move-
ments evoked by touch [63]. In our experiment, the head
of the embryo was embedded in agarose in such a way
that the trunk was not restricted in its movements. The
embryo was stimulated with an insect pin mounted on a
micromanipulator (Narishige; East Meadow, NY, USA).
The stimulus was repeated 5 times at 1 s intervals and
recorded using a high-speed digital video camera (Pix-
elink; Ottawa, ON, Canada) at 100 frames per second.
Movies were analyzed using Quicktime (Apple) and indi-
vidual frames were assembled for presentation in Adobe
Photoshop.
Results
met is expressed in a subset of zebrafish spinal 
motoneurons
met expression began in 1–2 cells in the ventral region of
each spinal hemisegment at 22 hpf (Figure 2a), but within
a few hours it was expressed in many more cells (Figure
2c). To learn which cells were met-positive, we first asked
whether met is co-expressed with islet2, a specific marker
of CaP and VaP at 22 hpf [60]. We found, as previously
reported [51] that at this stage met  was specifically
expressed in CaP and VaP (Figure 2b), but not in other
PMNs. However, by 26 hpf, met was expressed in all PMNs
(Figure 2c). Later, by 48 hpf, met was detectable in clusters
of four to eight cells in the ventral region of each spinal
hemisegment (Figure 2d). To determine whether these
Met appears unnecessary for muscle and neuromuscular  junction formation Figure 4
Met appears unnecessary for muscle and neuromus-
cular junction formation. (a,b) Engrailed antibody (Eng, 
red) labeling showing muscle pioneer cells and znp1 antibody 
labeling showing motor axons (green). In met MO-injected 
embryos, some CaP axons are truncated (asterisk). (c,d) F59 
antibody (red) labeling showing fast muscle fibers and znp1 
antibody staining showing motor axons (green). F59 labeling 
appears the same in control (c) and met MO-injected (d) 
embryos, which have some truncated CaPs (asterisk). (e-f) 
αBTX (red) labeling showing AChRs and znp1 antibody labe-
ling showing motor axons (green). The distribution of AChRs 
appears the same in control (e) and met MO-injected 
embryos (f) that have some truncated CaP axons (asterisks); 
however, it appears that the number of AChRs may be 
decreased at the myoseptal varicosity (arrows) by MO injec-
tion. For each experiment, 8 spinal hemisegments plus 
somites were examined in each of 21–33 met MO-injected 
embryos and 8 spinal hemisegments plus somites in each of 
15 controls. Scale bar, 20 μm.
Met is required for normal CaP axons Figure 5
Met is required for normal CaP axons. (a-b') 
Embryos at 26 hpf showing PMN axons labeled with 
znp1 antibody. met MO-injected embryos have normal MiP 
axons [arrow in (b')] compared to controls [arrow in (a')]. 
However, some CaP axons are truncated in met MO-injected 
embryos [asterisk in (b)] compared to controls (a). (c-d') 
Embryos at 48 hpf showing PMN and SMN axons labeled 
with znp1 antibody. As at 26 hpf, dorsally projecting axons in 
met MO-injected embryos appear normal [arrow in (d')] 
compared to controls [arrow in (c')]. However, some ven-
trally projecting axons are truncated in met MO-injected 
embryos [asterisk in (d)], compared to controls (c). (e) 
Average percentage of truncated axons in control and met 
MO-injected embryos at 26, 36 and 48 hpf. n (26 hpf) = 8 
somites in each of 12 embryos; n (36 hpf) = 8 somites in each 
of 10 embryos; n (48 hpf) = 8 somites in each of 11 embryos. 
Scale bar, 20 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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met-positive cells were SMNs, we used transgenic embryos
that express green fluorescent protein (GFP) under the
control of the gata2 promoter [Tg(gata2:GFP)], which has
been shown to be expressed in ventrally-projecting SMNs
[52] (Figure 2e) and in some interneurons [53], and is
routinely used to study SMN development
[65,47,66,46,67,68]. We also used embryos of the mn2Et
line that express GFP under the control of the parg pro-
moter [52] (Figure 2f). GFP has been previously reported
to be expressed specifically in CaP in the mn2Et line [52].
However, we find that, in this line, GFP is expressed in all
zebrafish PMNs (Figure 2g–j), and in at least some
zebrafish SMNs (Figure 2j). At 48 hpf, in mn2Et embryos
all met-positive cells co-expressed GFP, but not all GFP-
positive cells expressed met (Figure 2f) suggesting that met
is expressed in at least some SMNs. We also found that
many, but not all, met-positive cells co-expressed
gata2:GFP (Figure 2e); cells expressing met mRNA but not
GFP in Tg(gata2:GFP) embryos are probably PMNs and
dorsally projecting SMNs that are gata2:GFP-negative.
Together these results provide evidence that met is initially
expressed only in CaPs and VaPs, but soon after it is
expressed in other PMNs and later it is expressed in SMNs.
These results do not allow us to conclude whether or not
met  is ever expressed by dorsally-projecting SMNs. In
addition, because SMNs are born over a protracted period
of development [43], we also cannot conclusively deter-
mine whether met is expressed by all ventrally-projecting
SMNs or only by a subset of these cells.
Met is required for normal touch-evoked behavior
Expression of met  in PMNs and at least some SMNs
prompted us to ask whether Met function is necessary for
proper regulation of motoneuron-mediated behaviors.
Zebrafish embryos begin to exhibit spontaneous muscle
contractions that result in coiling movements shortly after
PMN axons first extend out of the spinal cord [69-71];
spontaneous coiling requires functional PMNs [71]. met
MO-injected embryos had normal spontaneous coiling,
suggesting that some PMNs were present and functional.
At later stages of development, embryos stop coiling spon-
taneously and instead respond to touch on the head or tail
[71]. Therefore, we compared motility of control and met
MO-injected embryos at 28–30 hpf, a stage at which con-
trol embryos are touch-responsive but no longer coil
spontaneously. Control embryos responded to tail touch
with a stereotyped bend of the trunk (see [70]); the aver-
age time for completing the stereotyped movement was
about 50 ms (Figure 3a,b). met MO-injected embryos had
impaired tail touch-evoked motility (Figure 3a,b). They
moved slower, with an average time for completing the
movement of 190 ms, and often had spasmodic move-
ments instead of the smooth bending seen in controls.
The time-course of the touch-evoked behavioral response
was significantly different between met MO-injected and
control embryos, but was not significantly different
between met mismatch MO-injected and control embryos
(Figure 3d), showing that normal Met function is required
for proper tail touch-evoked movements.
Even though met MO-injected embryos responded signif-
icantly slower to tail touches than did control embryos,
their ability to move suggested that muscle function was
normal and that neuromuscular junctions were present.
We verified this by labeling 26 hpf control and met MO-
injected embryos with zn1 or znp1 antibodies that recog-
nize zebrafish PMNs [69,72] and antibodies that recog-
nize specific muscle cell types, including anti-Engrailed
that recognizes a specific subset of slow muscle fibers
[62,73] (Figure 4a,b), and F59, that recognizes fast muscle
fibers (Figure 4c,d) [74]. PMNs were present in met MO-
Met is required for secondary motoneuron formation Figure 6
Met is required for secondary motoneuron forma-
tion. (a-b') gata2:GFP (green) transgenic embryos at 48 hpf 
labeled with antibody to Alcam (red). gata2:GFP is expressed 
in ventrally projecting SMNs, some of which also express 
Alcam (a); (a') shows only the GFP. met MO-injected 
embryos (b,b') show a severe decrease in SMNs, but Alcam 
labeling of the floor plate appears normal. A small number of 
SMNs form and make ventral projections (arrow). (b) Both 
markers shown; (b') only GFP shown. (c,c'). Some of the 
GFP-positive cells in met MO-injected embryos show 
interneuron-like axons. (c) An interneuron with an ascending 
axon; (c') an interneuron with a descending axon. The two 
GFP-positive cells to the right in (c') are SMNs. (d-g) 
gata2:GFP transgenic embryos (green) at 48 hpf labeled with 
Alcam antibody (red). Exposure to SB203580 (f) severely 
decreased the formation of SMNs relative to controls (d), 
but the overall architecture of the spinal cord appeared nor-
mal based on expression of GFP driven by the pax2a pro-
moter (e,g). Scale bar, 20 μm in all panels except (c,c'), which 
is 10 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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injected embryos, although in some cases CaP axons were
truncated (see below). Engrailed and F59 labeling were
both present in met MO-injected embryos and appeared
similar to controls. We also examined the localization of
AChR clusters using αBTX [75]. AChR clusters were
present in met MO-injected embryos and had a similar
distribution as in controls (Figure 4e,f). Together these
observations raise the possibility that Met function is not
required for formation of muscles or neuromuscular junc-
tions and that the impaired tail touch-evoked motility of
met MO-injected embryos resulted from a requirement for
Met for normal differentiation of PMNs, SMNs or both.
Met plays a role in formation of ventral motor nerves
To learn whether Met is required for normal differentia-
tion of PMNs and/or SMNs, we labeled 26 hpf and 48 hpf
embryos with the znp1 antibody, which reveals primary
and secondary motor axons [76]. By 26 hpf, PMN axons
had extended both ventrally and dorsally in control
embryos (Figure 5a,a'). In met MO-injected embryos, dor-
sally projecting MiP axons appeared normal, but some
ventrally extending CaP axons were truncated (Figure
5b,b'). However, only about 25% of CaP axons were
affected by Met knock down (Figure 5e).
By 48 hpf, SMNs had formed both dorsal and ventral
motor nerves (Figure 5c–d'). In met MO-injected embryos
the ventral nerves appeared thinner than in control
embryos (Figure 5c,d). Because znp1 labels both PMNs
and SMNs, and in 75% of hemisegments CaP axons had
extended normally, this result suggests that at least some
SMN ventral axons were truncated or failed to extend
when Met was knocked down. In addition, there were
some truncated ventral nerves. Previous studies showed
that CaP is unnecessary for extension of SMN ventral
axons [42]. Thus, the truncated ventral nerves could repre-
sent truncated CaP axons in segments in which SMN
axons failed to extend. Alternatively, they could represent
a combination of truncated CaP and truncated SMN
axons. Together these observations suggest that Met is
important for normal ventral axon extension by both
PMNs and SMNs. We provide further tests of this hypo-
thesis below.
Normal secondary motoneuron differentiation requires 
Met signaling
To learn whether Met was required for normal SMN devel-
opment, we examined SMNs in met  MO-injected
Tg(gata2:GFP) embryos at 48 hpf. We also labeled these
embryos with an antibody to Alcam, a cell surface protein
expressed on floor plate and transiently on the somata
and fasciculated segments of SMN axons [77]. In 48 hpf
Tg(gata2:GFP) embryos, most of the GFP-positive SMN
somata were also Alcam-positive (Figure 6a,a'). However,
there were many more Alcam-positive somata than GFP-
expressing somata, consistent with the observation that
gata2-driven GFP is expressed in ventrally projecting
SMNs but not in dorsally-projecting SMNs [53,66,67]. In
addition,  Tg(gata2:GFP)  embryos had some dorsally-
located, GFP-expressing somata that were Alcam-negative
(Figure 6a,a'). These cells could be SMNs that have down-
regulated Alcam expression or, alternatively, they might
be GFP-expressing interneurons [53]. In contrast to con-
trol  Tg(gata2:GFP)  embryos, in met  MO-injected
Tg(gata2:GFP) embryos the number of ventrally project-
ing SMN somata and axons was severely reduced (Figure
6b,b'; Table 1) and some of the GFP-positive somata pro-
jected interneuron-like axons within the spinal cord
rather than peripheral axons (Figure 6c,c'; Table 1). These
cells might be interneurons that normally express GFP in
this transgenic line. Alternatively, they could be SMNs
that have developed as interneurons. Consistent with the
latter possibility, the number of GFP-positive somata just
dorsal of the SMN soma domain (more than three cell
diameters dorsal of the floor plate) was increased in met
MO-injected embryos (Table 1). It is clear that in met MO-
injected embryos there are several types of GFP-positive
Table 1: The number of second motoneurons is reduced following Met knock down
Control met MO SB203580
Number of embryos 18 20 16
Percent of segments with ventral nerve 98 61 39
GFP+ somata within 3 cell diameters of floor plate 20 ± 0.47 9 ± 0.61 6 ± 0.40
GFP+ somata 3 cell diameters dorsal of floor plate 5 ± 0.39 10 ± 0.52 8 ± 0.68
GFP-positive SMN axons (three segments/embryo) and somata (two segments/embryo) were analyzed in 48 hpf Tg(gata2:GFP) embryos. Soma 
counts of treatment groups are all significantly different from controls (p < 0.00015).
Table 2: SB203580 affects SMN development
Number of embryos Percent of segments
with reduced SMN
somata
Control 75 0
met MO 96 80
U0126 20 0
SB203580 28 90
SMN somata were analyzed in three segments of each embryo at 48 
hpf. In all cases, the three segments had the same phenotype; in other 
words, within an embryo all segments had reduced SMN somata or 
no segments had reduced SMN somata.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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interneurons, because some of them have ascending
axons (Figure 6c) whereas others have descending axons
(Figure 6c'). To learn whether Met knock down caused
SMNs to die, we labeled embryos with acridine orange to
reveal dying cells [78] at 28, 36, and 48 hpf, but saw no
significant difference between the spinal cords of met MO-
injected embryos and controls (data not shown). In addi-
tion, the overall cellular structure of the spinal cord
appeared entirely normal in met  MO-injected embryos
(data not shown). Together these results suggest that Met
is required for formation of at least some SMNs and raise
the possibility that when Met is knocked down, at least
some SMNs develop as interneurons.
Met may mediate secondary motoneuron development 
through activation of p38 and/or Akt
Activation of the Met receptor can initiate signaling
through several different intracellular cascades (Figure 1)
[15,57,58]. To investigate which of these downstream
pathways is involved in SMN differentiation, we treated
embryos with compounds designed to inhibit specific
intracellular signaling cascades activated by Met and other
receptors, and assayed SMN development at 48 hpf. Spe-
cifically, we used U0126, which has been shown to inhibit
MEK1/2 (Figure 1) [35], and SB203580, which has been
shown to inhibit Akt and p38 (Figure 1) [34,36]. The
MEK1/2 inhibitor U0126 had no effect on SMN develop-
ment (Table 2 and data not shown), indicating that the
MEK1/2 pathway is not involved. In contrast, the Akt and
p38 inhibitor SB203580 dramatically affected SMN devel-
opment (Table 2). In fact, SMN development was even
more severely affected by blocking p38 and Akt signaling
than by knocking down Met function with MOs: inhibi-
tor-treated embryos were missing essentially all SMN
somata and axons (Figure 6d–g). There is some correctly
spliced met mRNA following MO injection (Figure 1), sug-
gesting that the more severe effect of the inhibitor could at
least partially result from a more complete knock down of
Met signaling than is achieved in met  MO-injected
embryos. This result also raises the possibility that in addi-
tion to Met, other pathways act upstream of p38 and/or
Akt during SMN formation. Future experiments to learn
the identities of these other pathways will help elucidate
the mechanisms required for normal SMN development.
In addition, zebrafish has two p38 genes, p38a and p38b,
that are broadly expressed at the stages of development we
have studied [79], raising the possibility that some effects
on SMNs could be cell non-autonomous. Thus, to test
whether SB203580 had a general effect on ventral spinal
cord neurons, we treated Tg(pax2a:GFP)  embryos [54]
with SB203580 and examined their spinal cords. Spinal
cord architecture appeared essentially normal in
SB203580-treated Tg(pax2a:GFP) embryos (Figure 6d–g)
suggesting that this inhibitor specifically affected SMNs.
Together these results suggest that Met may act through
Met is required for aspects of CaP identity Figure 7
Met is required for aspects of CaP identity. (a) A met 
MO-injected mn2Et (green) transgenic embryo labeled with 
znp1 antibody (red) showing that CaP has both a peripheral 
axon (arrow) and a central axon (asterisk). (a') The same 
cell showing only GFP. (a") The same cell showing only znp1 
labeling. (b,c) Islet1/2 antibody (Isl; red) and zn1 plus znp1 
antibodies (green) labeling showing that CaPs in met MO-
injected embryos (c) co-express these markers as they do in 
controls (b). For each condition we examined eight spinal 
hemisegments per embryo. n = 56 met MO-injected embryos 
and 32 control embryos. (d) chat is expressed in somata in 
the normal location of PMNs; gray lines show segment 
boundaries. (e,f) Expression of chat (green) and the CaP and 
VaP-specific marker islet2 (red) shows that in met MO-
injected embryos (f) CaPs express chat, as they do in con-
trols (e). For each condition we examined eight hemiseg-
ments per embryo. n = 24 met MO-injected embryos and 15 
control embryos. (g) Co-expression of chat (red) and met 
(green) in PMNs. Scale bars, 10 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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the Akt and/or p38 cascades to promote formation of
zebrafish SMNs.
Surprisingly, although SB203580-treated embryos lacked
most SMNs, at 30 hpf their tail touch-evoked motility was
essentially indistinguishable from control embryos (data
not shown). Only a few SMNs have projected axons by
this stage [42]; thus, this result suggests that at this stage
most of the touch response is mediated by activity of
PMNs, rather than by activity of SMNs, although this has
not yet been tested directly. If this is the case, then the
movement defects we observed at 30 hpf in met  MO-
injected embryos would have to arise from a requirement
for Met in PMN differentiation, rather than from the
decrease in SMN number. To test whether this was the
case, we examined the effects of Met knock down on PMN
development.
Met prevents CaPs from extending interneuron-like axons 
within the spinal cord
Despite the motility defects in met MO-injected embryos,
three quarters of the CaP axons looked essentially normal
as judged by their morphology (Figure 5), suggesting that
Met might be required for proper development of CaP
characteristics other than the peripheral axon. To learn
whether Met was required for differentiation of other fea-
tures of CaP morphology, we examined CaPs in met MO-
injected mn2Et embryos and we labeled embryos with zn1
and znp1 antibodies. Surprisingly, we found that many
CaPs had an interneuron-like process within the spinal
cord, in addition to the normal peripheral axon (Table 3;
Figure 7a–a"). To learn whether there was a correlation
between CaPs with truncated axons and those with
interneuron-like axons, we analyzed morphology of a
subset of CaPs (Table 4). There did not appear to be a cor-
relation, as we found that both CaPs with normal-appear-
ing peripheral axons and CaPs with truncated peripheral
axons had interneuron-like axons. These results suggest
that Met is important in maintaining CaP morphology by
preventing CaP from forming an interneuron-like central
process.
Met prevents CaPs from expressing an interneuron-
specific neurotransmitter
Based on their morphology, many CaPs in met  MO-
injected embryos appeared to have a hybrid identity that
combined features of both motoneurons and interneu-
rons. To learn whether this hybrid identity extended to
molecular features, we assayed two aspects of CaP: expres-
sion of Islet proteins and neurotransmitter phenotype. We
found that CaPs in met MO-injected embryos had normal
expression of Islet proteins (Figure 7b,c), suggesting that
they retained motoneuron identity. To learn whether
CaPs expressed normal cholinergic properties or
expressed interneuron-specific neurotransmitters, we tried
several antibodies to ChAT, the ACh synthetic enzyme,
but none of them worked in our hands. Because the chat
sequence is highly conserved within vertebrates, we used
the goldfish chat sequence [80] to blast zebrafish data-
bases (NCBI) and found a hypothetical sequence with
high homology to all vertebrate chat sequences. We ampli-
fied chat from zebrafish cDNA, verified the sequence and
found that it was expressed in cells with the correct posi-
tion and morphology to be PMNs (Figure 7d). We con-
firmed chat expression in CaPs using double fluorescent in
situ hybridization with islet2 (Figure 7e), and also con-
Table 3: Met knockdown results in CaPs with both peripheral and central axons
Number of 
embryos
Number of CaPs with
only a peripheral axon
Number of CaPs with
peripheral and central axons
Control 48 139 5
met MO 56 139 29
U0126 45 117 18
SB203580 27 81 0
CaPs were analyzed in 26 hpf mn2Et embryos; 3 hemisegments were examined per embryo.
Table 4: Whether CaP has an interneuron-like axon appears uncorrelated with whether it has a truncated peripheral axon
Control 
23 CaP axons in 6 embryos
met
MO 33 CaP axons in 10 embryos
U0126
55 CaP axons in 8 embryos
Peripheral axon
extended to
No interneuron-
like axon
Interneuron-
like axon
No interneuron-
like axon
Interneuron-
like axon
No interneuron-
like axon
Interneuron-
like axon
Ventral edge of muscle 22 1 17 8 36 10
Horizontal myoseptum 1 0 1 1 5 2
Just out of neural tube 0 0 4 2 2 0
Axons were analyzed in mn2Et embryos at 26 hpf.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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Met is required to prevent CaPs from expressing an inappropriate neurotransmitter Figure 8
Met is required to prevent CaPs from expressing an inappropriate neurotransmitter. For each condition we 
examined eight spinal hemisegments per embryo. (a-c") Embryos at 26 hpf labeled with antibodies to GABA (red) and zn1 plus 
znp1 (green); (a',b',c') only the green channel is shown; (a",b",c") only the red channel of the micrographs shown in (a,b,c) is 
shown. CaPs expressed GABA in embryos injected with translation blocking (b-b") or splice blocking (c-c") met MOs, but not 
in controls (a-a"). Note that some CaPs in met MO-injected embryos also have ectopic axons within the spinal cord (arrows). 
(d-e") Embryos at 26 hpf labeled with riboprobes to gad1 (green) and islet2 (red). (d',e') Only the green channel is shown; 
(d",e") only the red channel of the micrographs shown in (d,e) is shown. In met MO-injected embryos, islet2-positive CaPs also 
express gad1 (e-e"), whereas these two genes are not co-expressed in CaPs of control embryos (d-d"). (f-g") Embryos at 26 
hpf labeled with antibodies to GABA (red) and zn1 plus znp1 (green). (f',g') Only the green channel is shown; (f",g") only the red 
channel of the micrographs shown in (f,g) is shown. CaPs do not express GABA in embryos co-injected with met MO and 
mMet mRNA (f-f"), but do express GABA in embryos co-injected with met MO and lacZ mRNA (g-g"). (h,i) Embryos at 26 hpf 
labeled with antibodies to GABA (red) and Islet (green). CaPs co-express Islet and GABA in met MO-injected embryos (i) but 
not in controls (h). n = 80 embryos in (a); n = 128 embryos in (b); n = 24–32 embryos each for (c,e,f,g); n = 20 embryos for (h); 
n = 35 embryos for (i). The phenotype was seen in 70% of embryos injected with the splice-inhibitor MO and 80% of embryos 
injected with translation-blockers; in affected embryos all segments showed the phenotype. Rescue was seen in 90% of 
embryos injected with mMet mRNA and 0% of embryos injected with lacZ mRNA. Scale bars, 10 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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firmed that CaPs co-express met and chat (Figure 7g). We
analyzed  chat  expression in CaPs in met  MO-injected
embryos at 24 hpf and found that it was unaltered relative
to controls (Figure 7e,f), showing that this aspect of CaP
identity did not depend on Met function.
We previously showed that in the absence of Islet1,
zebrafish PMNs develop interneuron-like axons rather
than their normal peripheral projections and that some of
these cells express the interneuron-specific neurotransmit-
ter GABA [81]. Therefore, we asked whether CaPs
expressed GABA when Met function is knocked down. We
found that in embryos injected with either translation
blocking or splice blocking met MOs, the majority of CaPs
and VaPs expressed GABA (Figure 8a–c") in contrast to
control embryos, in which no CaPs or VaPs expressed
GABA (Table 5). We confirmed this by showing that in
contrast to controls, in met MO-injected embryos CaPs
and VaPs co-expressed GABA and Islet (Figure 8h,i). We
assayed the time-course of GABA expression and found
that it was first visible at about 24 hpf, shortly after the
time at which met  is expressed in PMNs. Because the
GABA antibody cross-reacts with an antigen in the muscle
(see Figure 8a,b), we confirmed PMN expression of GABA
using a riboprobe to gad1, the synthetic enzyme for GABA
[48,82] (Figure 8d–e"). Expression of gad1 and GABA in
PMNs of met MO-injected embryos is in stark contrast to
control embryos, in which PMNs never express GABA
(Figure 8a–e"; see also [81]). To confirm that expression
of GABA in CaPs required Met function, we coinjected
mMet mRNA with met translation blocking MOs (Figure
8f–f") and found that this abolished GABA expression in
CaPs, whereas embryos coinjected with lacZ mRNA and
met MOs expressed GABA in CaPs (Figure 8g–g"). These
results show that not only do CaPs lacking Met function
have a motoneuron/interneuron hybrid axonal morphol-
ogy, they also express both motoneuron and interneuron
neurotransmitters.
GABA expression in CaP may be regulated by the MEK1/2 
but not by the p38 or Akt pathways
We used pharmacological inhibitors to learn which Met-
activated intracellular signaling pathway(s) transduced
the signal required to prevent GABA expression in CaP.
Embryos were exposed to inhibitors of these pathways
from 16–26 hpf, then fixed and examined for expression
of GABA in CaPs (Table 5). Exposure to the MEK1/2 sign-
aling inhibitor U0126 resulted in GABA-positive CaPs,
similar to results observed in met MO-injected embryos
(Figure 9a–c"). In addition, some CaPs in U0126-treated
Table 5: CaPs express GABA in embryos in which Met is 
knocked down
Number of
embryos
Percent of 
GABA+ CaPs
Control 135 0
met MO 88 70
U0126 56 85
SB203580 88 0
CaPs were analyzed in four segments of each embryo. In all cases, 
CaPs in all four segments had the same GABA phenotype; they were 
either all GABA+ or all GABA-.
Met signaling may influence CaP axonal and neurotransmitter  phenotypes through the MEK1/2 pathway Figure 9
Met signaling may influence CaP axonal and neuro-
transmitter phenotypes through the MEK1/2 path-
way. All panels show mn2Et transgenic embryos. (a-d") 
Embryos at 26 hpf showing GFP (green) and GABA (red); 
asterisks indicate CaPs or CaP/VaP pairs. (a',b',c',d') Only the 
green channel is shown; (a",b",c",d") only the red channel of 
the micrographs shown in (a,b,c,d) is shown. CaPs express 
GABA in U0126-treated embryos (c-c") and met MO-
injected embryos (b-b") but not in controls (a-a") or in 
SB203580-treated embryos (d-d"). (e-h) Some CaPs have 
both peripheral (arrows) and central (asterisks) axons in 
U0126-treated embryos (g) and met MO-injected embryos 
(f); CaPs have only have peripheral axons in controls (e) and 
in SB203580-treated embryos (h). Scale bars, 10 μm.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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embryos had both peripheral and central axons, similar to
met MO-injected embryos (Table 3; Figure 9e–g). Together
these results suggest that the CaP axonal and neurotrans-
mitter phenotypes seen in the absence of Met function are
likely to result from lack of Met activation of MEK1/2. We
also treated embryos with SB203580, which inhibits the
Akt and p38 pathways and blocked SMN development. In
contrast to the effect of U0126, CaPs in embryos exposed
to SB203580 had the same neurotransmitter (Figure 9d–
d"; Table 5) and axonal (Figure 9h; Table 3) phenotype as
control CaPs, suggesting that signaling via p38 and Akt is
not involved in regulating CaP neurotransmitter and axon
phenotype.
Discussion
We report two key findings about the role of the Met
receptor tyrosine kinase in motoneuron development.
First, Met is required for formation of some zebrafish
SMNs. Our experiments suggest that this role of Met acts
through the p38 and/or Akt signaling cascade. Second,
Met is required to prevent CaP motoneurons from co-
expressing features of motoneurons and interneurons,
including axon pathway and neurotransmitter phenotype.
Our experiments suggest that this role of Met acts through
the MEK1/2 signaling cascade. We discuss each of these
observations in turn.
Met is necessary for formation of some zebrafish 
secondary motoneurons
In chick, mouse, and rat, Met is expressed in a subset of
spinal motoneurons and the Met ligand HGF is important
for the differentiation of these cells [14,16,17,19]. Met
appears to be expressed primarily in limb-innervating lat-
eral motor column motoneurons and HGF acts as a che-
moattractant for the axons of these cells in vitro and in vivo,
as well as promoting their survival through the period of
normal programmed cell death when tested in vitro
[16,17,19].
In zebrafish, met is also expressed in a subset of spinal
motoneurons, in this case in all primary and at least some
secondary motoneurons of the medial motor column. In
the case of SMNs, Met appears to be required for forma-
tion of these cells, as their number is significantly reduced
when Met activity is knocked down; whether or not this is
the case for the HGF-dependent limb-innervating
motoneurons of chick, mouse, or rat has not been
reported. The decrease in SMN number when Met is
knocked down might result from death of SMNs or their
progenitors. We did not see increased cell death, suggest-
ing an alternative possibility that SMNs differentiated as
interneurons, as we have previously seen in the absence of
Islet1 [81] or Nkx6 proteins [65,83]. Consistent with this
possibility, at 48 hpf there were more interneuron-like
axons within the spinal cord and somata in positions con-
sistent with spinal interneurons in Tg(gata2:GFP)
embryos injected with met MOs than in Tg(gata2:GFP)
control embryos.
To begin to learn which intracellular signaling pathways
may be involved in Met-mediated SMN formation, we
exposed embryos to inhibitors that act on specific path-
ways downstream of Met activation. Our results suggest
that the p38 and/or Akt pathways are required for normal
development of SMNs. However, a caveat to this interpre-
tation is that the phenotype was much more severe when
these pathways were blocked than when Met was knocked
down using MOs. One possible explanation is that Met
was incompletely knocked down by our MOs but com-
pletely blocked by the pharmacological inhibitor. Alterna-
tively, because these pathways are activated by other
receptors in addition to Met, pharmacological blockade
may lead to more widespread effects, including effects
that are non cell-autonomous (see below). In the future it
will be important to learn which other receptors activate
these pathways in SMNs and how this is related to activa-
tion of these pathways by Met. Finally, the expression of
both zebrafish p38 genes is widespread throughout early
development [79], raising the possibility that p38 acti-
vated pathways could have both cell-autonomous and
non cell-autonomous effects on SMN development.
Met prevents primary motoneurons from expressing 
interneuron-like properties
We have previously found that knocking down function
of several transcription factors expressed in PMNs, and in
some cases in their progenitors, results in these cells
expressing interneuron-like properties. Thus, in the
absence of Islet1, PMNs develop interneuron-like axons
within the spinal cord, rather than peripheral axons, and
many of these cells express the interneuron neurotrans-
mitter GABA [81]. Similarly, in the absence of Nkx6 tran-
scription factors, MiPs develop a hybrid phenotype in
which they have both peripheral axons that innervate
muscle and central axons that extend within the spinal
cord, although these cells do not express GABA [83]. Here
we report that knocking down Met function causes CaPs
to express a hybrid phenotype in which many of them
have both a peripheral axon innervating muscle and a
central axon extending within the spinal cord. In addition,
these cells co-express cholinergic and GABAergic proper-
ties. Despite expression of GABA, PMNs are still able to
activate muscle in the absence of Met function. However,
the touch response is significantly slower than in control
embryos at developmental stages at which this behavior is
likely to be mediated primarily by PMNs. Thus, this
slower response is probably a result of impairment in
PMN function.Neural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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The ability of PMNs to develop a hybrid phenotype in the
absence of Met reveals a degree of plasticity not previously
reported for motoneurons. Previous studies showed that
the absence of specific transcription factors in motoneu-
ron progenitors [9,84-89] or in newly post-mitotic
motoneurons [83] allows these cells to co-express
motoneuron and interneuron properties. These studies
reveal the importance of specific transcription factors in
preventing motoneurons from developing interneuron
properties early in their development. Other studies have
shown that postmitotic motoneurons can change their
identity from one motoneuron subtype to another in
response to environmental cues [90] and that environ-
mental signals can override genetic programs and cause
motor axons to extend along aberrant pathways [91].
These studies reveal plasticity in motoneuron subtype
specification. In contrast, here we show that motoneurons
are able to express interneuron-like properties at late
stages of development. Zebrafish met  is expressed in
PMNs about 6–8 hours after they initially extend growth
cones and after their axons have extended to and inner-
vated their specific target muscles. Thus, our studies raise
the question of whether the ability to develop interneuron
characteristics long after their peripheral axons innervate
their muscle targets is a general feature of motoneurons. It
is well-known that at least some neural crest-derived
peripheral neurons have long-lived phenotypic plasticity
[10,11], but it is not typically believed that this is the case
for central neurons. This issue is particularly important
because a recent study has shown that forcing motoneu-
rons to release neurotransmitters other than ACh causes
their muscle targets to express receptors to the motoneu-
ron-expressed neurotransmitters [7], potentially leading
to inappropriate muscle responses to motoneuron activa-
tion.
The late expression of met in PMNs raises the interesting
question of what prevents CaPs from extending interneu-
ron-like axons and expressing GABA at stages prior to met
expression. Although we do not have an answer to this
question, we hypothesize that many different factors are
required to prevent motoneurons from expressing
interneuron-like properties. Consistent with this hypo-
thesis, several transcription factors, including Islet1 [81],
Nkx6 [85,88,65,83], Lhx3 [9], Hb9 [9] and AML1/Runx1
[89] have been shown to prevent various types of motone-
urons from adopting interneuron-like properties. It is not
yet clear, but will be exciting to learn, the identities of the
downstream targets of these transcription factors and how
they regulate different aspects of interneuron develop-
ment. We predict that different downstream targets pre-
vent motoneurons from expressing different interneuron
properties at different developmental stages. We have pro-
posed that zebrafish PMNs have a high propensity to
develop into motoneuron/interneuron hybrids because,
as has been postulated from studies in mammals [86],
zebrafish motoneurons are closely-related to specific
types of interneurons [83]. In zebrafish and chick, both
motoneurons and interneurons can arise from a single
progenitor [92-94]; whether this is also the case in mam-
mals is unknown because single progenitor labeling
experiments have not been reported.
GABA expression in developing motoneurons
Although vertebrate motoneurons are generally consid-
ered exclusively cholinergic, several recent studies provide
evidence that mammalian spinal motoneurons can
release both ACh and glutamate at central synapses on
Renshaw cells [4-6]. However, ACh is still thought to be
the only neurotransmitter that mediates motoneuron acti-
vation of skeletal muscle [4-6]. Thus, it is surprising that
during early development, frog muscles express not only
AChRs at the nascent neuromuscular junction (NMJ) but
also several other types of neurotransmitter receptors,
including glutamate receptors, glycine receptors and
GABA receptors [7]. From experiments in which they
altered motoneuronal neurotransmitter expression, Boro-
dinsky and Spitzer [7] have argued that the final comple-
ment of receptors at the NMJ results from matching the
neurotransmitter released by motoneurons with the
receptors on muscle cells. In their studies, they never saw
GABA expression by motoneurons under control condi-
tions. However, several earlier studies reported transient
expression of GABA in motoneurons in chick, monkey
[95] and rat [96]. GABA may act not only as a neurotrans-
mitter, but also as a trophic factor during development
[97,98], and it may be important for integrating develop-
ing neurons into circuits [99]. These features might
explain early transient expression in neurons that do not
normally use GABA as a neurotransmitter. However, nei-
ther we nor others have reported GABA expression in
zebrafish spinal motoneurons, and the issue of whether
transient GABA expression is a common feature of verte-
brate spinal motoneurons remains unresolved.
Conclusion
It has been known for many years that environmental sig-
nals can alter subtype specification in newly post-mitotic
motoneurons [90]. Here we show that motoneurons
retain the ability to develop interneuron-like characteris-
tics, including both axon trajectory and neurotransmitter
phenotype, long after they have innervated their muscle
targets. In zebrafish, motoneurons and some types of
interneurons are generated from the same progenitor
domain [92-94], and previous studies showed that in the
absence of Notch signaling motoneurons are the preferred
fate of cells within that domain [94,100]. Here we suggest
that despite this, motoneurons may require continuous
signaling to prevent them from developing interneuron-
like properties. Our current results also show thatNeural Development 2008, 3:18 http://www.neuraldevelopment.com/content/3/1/18
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motoneurons that co-express interneuron-like properties
can still innervate target muscle. In addition, we suggest
that the Met receptor tyrosine kinase acts through differ-
ent intracellular signaling cascades to affect distinct
aspects of development in different motoneuron sub-
types.
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